Who are Second-line systemic therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tevimbra, Penpulimab kcqx, Unloxcyt, Loqtorzi, Jemperli, Libtayo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/second-line-systemic-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Second-line systemic therapy — Competitive Intelligence Brief

Second-line systemic therapy (Second-line systemic therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor. Area: Oncology.

phase 3 PD-1 inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Second-line systemic therapy (Second-line systemic therapy) — Sun Yat-sen University. This drug targets the PD-1 receptor to inhibit cancer cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Second-line systemic therapy TARGET	Second-line systemic therapy	Sun Yat-sen University	phase 3	PD-1 inhibitor	PD-1
Tevimbra	TISLELIZUMAB	Beigene	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2025-01-01
Penpulimab kcqx	PENPULIMAB	Akeso Biopharma	marketed		Pd-1	2025-01-01
Unloxcyt	COSIBELIMAB	Checkpoint Therapeutics Inc	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	2024-01-01
Loqtorzi	TORIPALIMAB	Coherus Biosciences Inc	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2024-01-01
Jemperli	DOSTARLIMAB	GSK	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	PD-1	2021-01-01
Libtayo	CEMIPLIMAB	Regeneron Pharmaceuticals	marketed		PD-1	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor class)

Sun Yat-sen University · 11 drugs in this class
Bristol-Myers Squibb · 9 drugs in this class
Addpharma Inc. · 7 drugs in this class
Merck Sharp & Dohme LLC · 5 drugs in this class
Shanghai Henlius Biotech · 5 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 5 drugs in this class
Pfizer · 4 drugs in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 4 drugs in this class
Amgen · 3 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Second-line systemic therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/second-line-systemic-therapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab